

RHINOMED ATTENDANCE AT INTERNATIONAL INVESTOR CONFERENCES

KEY HIGHLIGHTS:

- **Rhinomed has been invited to exhibit at the 30th Annual ROTH Investor Conference in Orange County California, March 11-14th.**
- **Rhinomed has been invited to exhibit and present at the UK Master Investor Show in London, March 17th.**

March 2, 2018, Melbourne, Australia.

Australian nasal and respiratory technology company Rhinomed (ASX:RNO) is pleased to advise it will exhibit and present at two major investor conferences in the USA and the UK.

ROTH Investor Conference - USA

On March 11-14th Rhinomed will be exhibiting at the 30th Annual ROTH investor conference in Orange County, California. The Annual ROTH Investor conference is organized by Roth Capital Partners - one of the premier US based investment banking firms dedicated to the small cap public market. The conference is one of the best attended investor conferences in the USA attracting over 4,700 institutional investors, private equity, venture capital, family offices and high net worth investors who are all part of Roth's extensive client network in the USA.

Given Rhinomed's growing presence in some of America's leading pharmacy chains, this conference provides a unique opportunity for Rhinomed to showcase its technology investment proposition to US based investors.

Master Investor Conference - UK

On March 17th, Rhinomed will be both exhibiting and presenting at the 2018 UK Master Investor Show. The Master Investor Show is the UK's premier investor conference attended by over 5000 UK based private investors.

Rhinomed has been invited to attend the Master Investor Show by Rhinomed shareholder and one of the UK's leading investors, billionaire businessman Mr Jim Mellon. The show represents a unique opportunity to expose UK investors to Rhinomed's compelling medical technology proposition.

An investor presentation is currently being prepared for the Master Investor Show and will be released to the ASX prior to the 17th of March.

For personal use only

RHINOMED

MAKE EVERY BREATH COUNT

Media Enquiries

Michael Johnson, CEO & Director
+61 (03) 8416 0900
mjohnson@rhinomed.global

Follow us on **Twitter** @rhinomedceo

About Rhinomed Limited (ASX: RNO)

Rhinomed Limited is a Melbourne based technology firm with a focus on nasal, respiratory and breathing management technologies. The company is seeking to monetise applications of its technology portfolio in the Sport, Sleep, Wellbeing and Drug Delivery markets. For more information go to www.rhinomed.global

About the Turbine™

Turbine™ is a revolutionary respiratory technology designed specifically for the sport market. Turbine delivers an average increase of 38% more airflow through the nasal passages and has been designed for both professional and amateur athletes participating in sports and fitness activities ranging from triathlon, cycling, running and non-impact sports to elite training environments, such as altitude training. You can purchase a Turbine by visiting www.theturbine.com

About the Mute™

Mute™ is a unique nasal respiratory technology that has been found reduce the volume and frequency of snoring in 75% of users. Mute is easy to use, drug free and fits discreetly inside the nose. Designed to give snoring the silent treatment and made from ultra-soft polymers, Mute gently expands each nostril to increase the volume of air in each breath. By doing so, Mute encourages nasal breathing and reduces the need to open the mouth during sleep, factors critical to a reduction in snoring and better sleep quality. For more information or to purchase online, visit www.mutesnoring.com

For personal use only